Top Page
Aceso Life Science Group Limited
(0474)
Aceso Life Science Group Limited (0474) vs. iShares MSCI Hong Kong ETF (EWH)
Aceso Life Science Group Limited Business Overview & Revenue Model
Aceso Life Science Group Limited Financial Statement Overview
| Breakdown | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.00M | 312.00M | 315.00M | 346.00M | 295.64M |
| Gross Profit | -100.00M | 141.00M | 162.00M | 213.00M | 166.60M |
| EBITDA | -220.00M | -21.00M | -359.00M | -69.00M | -52.36M |
| Net Income | -462.00M | -264.00M | -370.00M | -376.00M | -283.72M |
Balance Sheet | |||||
| Total Assets | 4.79B | 6.30B | 6.26B | 6.17B | 5.03B |
| Cash, Cash Equivalents and Short-Term Investments | 466.00M | 602.00M | 717.00M | 786.00M | 581.02M |
| Total Debt | 2.74B | 2.34B | 3.01B | 2.76B | 2.20B |
| Total Liabilities | 2.97B | 3.73B | 3.44B | 3.15B | 2.54B |
| Stockholders Equity | 921.00M | 1.55B | 2.00B | 2.38B | 2.49B |
Cash Flow | |||||
| Free Cash Flow | -48.00M | 175.00M | 259.00M | 164.00M | -392.50M |
| Operating Cash Flow | -37.00M | 222.00M | 316.00M | 179.00M | -356.32M |
| Investing Cash Flow | 472.00M | -120.00M | -441.00M | -10.00M | 994.30M |
| Financing Cash Flow | 117.00M | -98.00M | 126.00M | -375.00M | -521.79M |
Aceso Life Science Group Limited Technical Analysis
Aceso Life Science Group Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $10.90B | 15.41 | 5.26% | 1.89% | 3.11% | -26.85% | |
56 Neutral | HK$248.00M | ― | -1.79% | 3.75% | -22.64% | -158.20% | |
54 Neutral | HK$181.01M | 33.87 | 0.21% | ― | -14.31% | ― | |
46 Neutral | HK$133.42M | ― | -29.12% | ― | 7.36% | -70.59% | |
39 Underperform | HK$258.36M | ― | -191.85% | ― | -9.49% | 5.90% | |
| ― | $20.58M | 10.00 | -20.46% | ― | ― | ― | |
50 Neutral | HK$1.21B | 37.34 | 2.65% | 1.35% | -60.81% | -21.00% |
Aceso Life Science Group Limited Corporate Events
Aceso Life Science Group Limited has received a demand letter from a bank regarding two loan agreements, one of which is significant to the company’s operations. The significant loan, amounting to HK$270 million, has not yet matured, but the bank has demanded repayment due to a cross-default provision. The company is in discussions with the bank for an extension and advises caution to shareholders and potential investors.
Aceso Life Science Group Limited has received a demand letter from a commercial bank in Hong Kong, requiring the company to repay approximately HK$352 million in debt by 31 March 2025. The company is currently seeking legal advice and negotiating with the bank to resolve the issue, while advising shareholders and potential investors to exercise caution.
Aceso Life Science Group Limited and Hao Tian International Construction Investment Group Limited have announced an extension of the long-stop date for the placing of new HTICI shares under a specific mandate. The new deadline is set for May 15, 2025, as more time is needed to finalize the list of placees. This extension indicates ongoing negotiations and adjustments in their strategic financial operations, potentially impacting stakeholders and market positioning.
Aceso Life Science Group Limited announced a delay in the dispatch of its circular, originally scheduled for release by April 23, 2025, now postponed to May 9, 2025. This delay is due to the need for additional time to finalize certain information, affecting shareholders and potential investors who are advised to exercise caution when dealing with the company’s securities.
Aceso Life Science Group Limited has announced a default on its facility agreements, with an outstanding principal amount of approximately GBP79.0 million. The company is actively seeking legal advice and exploring financial options to address the default, while advising shareholders and potential investors to exercise caution.
Aceso Life Science Group Limited announced the formation of a joint venture with Jiangsu Lettall, with HTICI, a subsidiary of Aceso, holding a 75% stake. This joint venture will become a subsidiary of Aceso, consolidating its financial results with the group. The transaction is considered a major one under the Hong Kong Listing Rules, requiring shareholder approval, which has been obtained from a group controlling over 57% of the company’s shares. The venture aims to strengthen Aceso’s market position and expand its operational scope.
Aceso Life Science Group Limited announced that the Ordinary Resolution proposed at their Extraordinary General Meeting (EGM) held on March 18, 2025, was successfully passed by shareholders. This resolution approves the Placing Agreement and related transactions, granting a specific mandate to Hao Tian International Construction Investment Group Limited’s directors for the issuance of Placing Shares. The approval reflects strong shareholder support, with 100% of votes cast in favor, potentially impacting the company’s strategic initiatives and market positioning positively.
Aceso Life Science Group Limited has announced an extraordinary general meeting to be held on March 18, 2025, to approve a placing agreement. This agreement involves Hao Tian International Construction Investment Group Limited issuing up to 1,524,224,000 new ordinary shares at a price of HK$0.4 per share. The meeting will seek shareholder approval for the directors to execute the agreement and related transactions, potentially impacting the company’s financial strategy and stakeholder interests.